Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MNPR, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Clonidine HCl Mucoadhesive Buccal Tablet | Chemoradiotherapy-Induced Severe Oral Mucositis | Phase 2/3 · NCT04648020 | Terminated |
| Camsirubicin | Advanced Soft-tissue Sarcoma | Phase 1 · NCT05043649 | Terminated |
| MNPR-101-DFO*-89Zr | Solid Tumor, Adult | Phase 1 · NCT06337084 | Active not recruiting |
| MNPR-101-PCTA-177Lu | Solid Tumor, Adult | Phase 1 · NCT06617169 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MNPR holds $129.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.7M/quarter from operations, an estimated runway of 82.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MNPR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | Institution (13G, 5%+) | 1,119,413 | 16.52% | 2026-09-30 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 667,632 | 9.85% | 2025-12-31 |
| AstraZeneca PLC | 5%+ holder (13G) | 522,667 | 7.71% | 2025-12-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 338,133 | 4.99% | 2026-09-30 |
| Tactic Pharma LLC 10% owner |
Insider | 272,026 | 4.01% | 2025-09-24 |
| Chandler Robinson Chief Executive Officer, Director · +336,934 options |
Insider | 166,942 | 2.46% | 2026-10-20 |
| Diane Hendricks 10% owner |
Insider | 93,750 | 1.38% | 2025-12-16 |
| Andrew Cittadine Chief Operating Officer · +135,351 options |
Insider | 58,054 | 0.86% | 2026-09-30 |
| Christopher M Starr Director · +11,324 options |
Insider | 15,053 | 0.22% | 2026-10-01 |
| Kim R Tsuchimoto Director · +13,139 options |
Insider | 11,486 | 0.17% | 2026-11-02 |
| Arthur J Klausner Director · +2,924 options |
Insider | 8,762 | 0.13% | 2025-12-18 |
| Raymond Anderson Director · +8,868 options |
Insider | 5,373 | 0.08% | 2026-11-02 |
Share count 6,776,773 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MNPR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →